Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus

Int J Impot Res. 2002 Dec;14(6):466-71. doi: 10.1038/sj.ijir.3900910.

Abstract

Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, has become a first-line therapy for diabetic patients with erectile dysfunction (ED). The efficacy in this subgroup, based on the Global Efficacy Question, is 56% vs 84% in a selected group of non-diabetic men with ED. Two novel PDE5 inhibitors, tadalafil (Lilly ICOS) and vardenafil (Bayer), have recently completed efficacy and safety clinical trials in 'general' and diabetic study populations and are now candidates for US FDA approval. A summary analysis of the phase three clinical trials of sildenafil, tadalafil and vardenafil in both study populations is presented to provide a foundation on which the evaluation of the role of the individual PDE5 inhibitors for the treatment of patients with ED and DM can be built.

MeSH terms

  • 3',5'-Cyclic-GMP Phosphodiesterases
  • Carbolines / adverse effects
  • Carbolines / therapeutic use*
  • Clinical Trials, Phase III as Topic
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • Diabetes Complications*
  • Erectile Dysfunction / complications*
  • Erectile Dysfunction / drug therapy*
  • Humans
  • Imidazoles / adverse effects
  • Imidazoles / therapeutic use*
  • Male
  • Multicenter Studies as Topic
  • Phosphodiesterase Inhibitors / adverse effects
  • Phosphodiesterase Inhibitors / therapeutic use*
  • Phosphoric Diester Hydrolases / drug effects*
  • Piperazines / adverse effects
  • Piperazines / therapeutic use*
  • Purines
  • Randomized Controlled Trials as Topic
  • Sildenafil Citrate
  • Sulfones
  • Tadalafil
  • Triazines
  • Vardenafil Dihydrochloride

Substances

  • Carbolines
  • Imidazoles
  • Phosphodiesterase Inhibitors
  • Piperazines
  • Purines
  • Sulfones
  • Triazines
  • Vardenafil Dihydrochloride
  • Tadalafil
  • Sildenafil Citrate
  • Phosphoric Diester Hydrolases
  • 3',5'-Cyclic-GMP Phosphodiesterases
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • PDE5A protein, human